Clonidine Treatment of Alzheimer's Disease

Erich Mohr, Paul Fedio, Jerry Schlegel, Giovanni Fabbrini, Jill Williams, M. Maral Mouradian, Ulrike M. Mann, Jules J. Claus, Thomas N. Chase

Research output: Contribution to journalArticle


A loss of cortical noradrenergic innervation may contribute to the intellectual deterioration in Alzheimer's disease. To test the hypothesis that noradrenergic replacement may confer symptomatic benefit, a double-blind, placebo-controlled therapeutic trial with clonidine hydrochloride (Catapres), a centrally active noradrenergic receptor agonist, was undertaken in eight patients with the clinical diagnosis of Alzheimer's disease. No statistically significant changes in cognitive function were found over a range of doses, including those that produced clinically observable side effects. These preliminary results indicate a need for alternative noradrenergic replacement strategies in Alzheimer's disease.

Original languageEnglish
Pages (from-to)376-378
Number of pages3
JournalArchives of Neurology
Issue number4
Publication statusPublished - 1989

ASJC Scopus subject areas

  • Arts and Humanities (miscellaneous)
  • Clinical Neurology
  • Neuroscience(all)

Fingerprint Dive into the research topics of 'Clonidine Treatment of Alzheimer's Disease'. Together they form a unique fingerprint.

  • Cite this

    Mohr, E., Fedio, P., Schlegel, J., Fabbrini, G., Williams, J., Mouradian, M. M., Mann, U. M., Claus, J. J., & Chase, T. N. (1989). Clonidine Treatment of Alzheimer's Disease. Archives of Neurology, 46(4), 376-378.